Several different kinds of chemotherapy drugs are used in combination with TRAIL to sensitize TRAIL-resistant cancer cells, and many reports have combined recombinant TRAIL with standard anticancer therapies to induce synergistic tumor cell apoptosis [ 10, 11].
Further, we confirmed that small-molecule inhibition of SRC or BCL2L1, in combination with TRAIL, sensitizes breast cancer cells to TRAIL-induced apoptosis, including cell lines resistant to TRAIL-induced cytotoxicity.
Whereas abundant data therefore support the combination of TRAIL with cytotoxic drugs, only limited studies of TRAIL combined with ionising radiation have been performed [ 31, 33, 60- 62].
Therefore, identification of PDPK1 as one of the key nodes provides a rationale for pursuing studies on the combination of TRAIL with AKT inhibitors in treatment of TRAIL-resistant tumors.
These findings indicate that in vitro melanoma cells resistant to the combination of TRAIL with SMAC-mimetics can be killed by the combined effects of Bortezomib and SMAC-mimetic.
Therefore, we next studied whether a combination of TRAIL with genotoxic agents could induce cytotoxicity in #63 glioma cells, which were resistant to TRAIL-induced cell death.
To test whether other PIs could exhibit a similar robust proapoptotic activity when used in combination with TRAIL, we chose NCI-H28 as a representative in the treatment with 30 nM Bortezomib and 5 ng/ml TRAIL.
He completed it through a combination of trail running and free-soloing, or climbing without a rope.
The use of TPGS in combination with TRAIL and endostatin had synergistic antitumor effects.
In the study, a combination of TRAIL and a histone deacetylase inhibitor LBH589 was studied in mesothelioma cell lines.
